Comparative genomics and transcriptome profiling in primary aldosteronism by Prada, E. T. A. et al.
 International Journal of 
Molecular Sciences
Review
Comparative Genomics and Transcriptome
Profiling in Primary Aldosteronism
Elke Tatjana Aristizabal Prada 1, Isabella Castellano 2, Eva Sušnik 1, Yuhong Yang 1,
Lucie S. Meyer 1, Martina Tetti 3, Felix Beuschlein 1,4, Martin Reincke 1 and Tracy A. Williams 1,3,*
1 Medizinische Klinik und Poliklinik IV, Klinikum der Universität, Ludwig-Maximilians-Universität
München, 80336 Munich, Germany; elke_tatjana_aristizabal.prada@med.uni-muenchen.de (E.T.A.P.);
Eva.Susnik@med.uni-muenchen.de (E.S.); Yuhong.Yang@med.uni-muenchen.de (Y.Y.);
Lucie.Meyer@med.uni-muenchen.de (L.S.M.); Felix.Beuschlein@med.uni-muenchen.de (F.B.);
Martin.Reincke@med.uni-muenchen.de (M.R.)
2 Division of Pathology, Department of Medical Sciences, University of Torino, 10124 Torino, Italy;
isabella.castellano@unito.it
3 Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Torino,
10126 Torino, Italy; marty_queen@alice.it
4 Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, UniversitätsSpital Zürich, CH-8091
Zurich, Switzerland
* Correspondence: Tracy.Williams@med.uni-muenchen.de; Tel.: +49-089-440-052-941
Received: 15 February 2018; Accepted: 6 April 2018; Published: 9 April 2018


Abstract: Primary aldosteronism is the most common form of endocrine hypertension with a
prevalence of 6% in the general population with hypertension. The genetic basis of the four familial
forms of primary aldosteronism (familial hyperaldosteronism FH types I–IV) and the majority of
sporadic unilateral aldosterone-producing adenomas has now been resolved. Familial forms of
hyperaldosteronism are, however, rare. The sporadic forms of the disease prevail and these are
usually caused by either a unilateral aldosterone-producing adenoma or bilateral adrenal hyperplasia.
Aldosterone-producing adenomas frequently carry a causative somatic mutation in either of a number
of genes with the KCNJ5 gene, encoding an inwardly rectifying potassium channel, a recurrent target
harboring mutations at a prevalence of more than 40% worldwide. Other than genetic variations, gene
expression profiling of aldosterone-producing adenomas has shed light on the genes and intracellular
signalling pathways that may play a role in the pathogenesis and pathophysiology of these tumors.
Keywords: primary aldosteronism; aldosterone; aldosterone-producing adenoma; transcriptome profiing
1. Introduction
Primary aldosteronism (PA) is the most common potentially curable form of hypertension with
a prevalence of 5–10% in patients with hypertension [1–3] and is characterized by the excessive
production of aldosterone. Aldosterone excess has detrimental effects independent of blood pressure
control as demonstrated by the increased risk of cardiovascular and cerebrovascular events and target
organ damage in patients with PA relative to matched patients with essential hypertension. PA is
mainly caused by either an aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia
(BAH). The diagnosis of an APA is appealing because hypertension can be cured or markedly improved
by unilateral adrenalectomy and resolve the aldosterone excess in the majority of cases [4]. In contrast,
patients with BAH are usually treated with a mineralocorticoid receptor antagonist but plasma renin
levels should be monitored as a therapeutic response (as well as blood pressure) because suppressed
renin, independent of blood pressure control, is associated with an increased risk of cardiometabolic
events and death relative to patients with essential hypertension [5]. A landmark in PA research was
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the discovery of germline and somatic mutations that drive the aldosterone overproduction in patients
with PA, discoveries that were made possible by the application of next-generation sequencing [6–12].
The genetic basis of four familial forms of PA has now been described as well as somatic mutations in
APAs and these are discussed in more detail below.
Herein, we outline novel contributions and major discoveries that have been made in the
field of PA research over the last few years. We describe the genetic basis of familial forms of
hyperaldosteronism and the identification of somatic mutations that lead to excess aldosterone
production. Differential gene expression profiles between APAs and reference tissues are highlighted,
as well as key signalling pathways and molecular mechanisms that may drive cell proliferation and
constitutive aldosterone production in APAs. Additionally, the possible influence of genetics and
genomics on surgical outcome and the potential application of next-generation sequencing methods
and transcriptome profiling as possible prognostic tools are described.
2. Synthesis of Aldosterone
The primary function of aldosterone is to maintain fluid and electrolyte balance for the control
of blood pressure. The main physiological regulators of aldosterone synthesis are angiotensin
II, potassium and adrenocorticotropic hormone. Aldosterone synthesis is restricted to the zona
glomerulosa (ZG), the outer layer of the adrenal cortex (Figure 1) where aldosterone synthase converts
deoxycorticosterone to aldosterone by three successive steps of 11β-hydroxylation, 18-hydroxylation
and 18-oxidation by a single enzyme, aldosterone synthase (encoded by CYP11B2). CYP11B2 displays
a high level of intron and exon sequence homology to the CYP11B1 gene localized in the zona fasciculata
(ZF) that encodes 11β-hydroxylase that catalyses the final step in the conversion of 11-deoxycortisol to
cortisol (Figure 1). Angiotensin II and potassium regulate aldosterone production via Ca2+ signalling
which also plays a key role in the aldosterone excess in PA due to the somatic and germline mutations
in ion channels and transporters.
Figure 1. Aldosterone synthesis in the adrenal cortex. Aldosterone is synthesized in the zona glomerulosa
(ZG) distinct from the synthesis of cortisol in the zona fasciculata (ZF). Aldosterone synthase encoded by
CYP11B2 performs all three enzymatic steps in the conversion of deoxycorticosterone to aldosterone.
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3. Familial Forms of Hyperaldosteronism
There are currently 4 recognised forms of familial hyperaldosteronism (FH types I–IV) and the
genetic basis of each type is summarized in Table 1.
Table 1. Familial forms of hyperaldosteronism.
Subtype of Primary Aldosteronism Genetic Variant Encoded Protein Brief Description
FH Type I CYP11B1/CYP11B2hybrid gene CYP11B2
Ectopic expression in ZF;
regulated by ACTH
FH Type II CLCN2 mutations CIC-2 Chloride voltage-gatedchannel 2
FH Type III KCNJ5 mutations GIRK4
Potassium Voltage-Gated
Channel Subfamily J
Member 5
FH Type IV CACNA1H mutations Cav3.2 Calcium Voltage-GatedChannel Subunit α1H
3.1. Familial Hyperaldosteronism Type I
Familial hyperaldosteronism type I (FH type I or GRA, glucocorticoid remediable aldosteronism)
is caused by a hybrid CYP11B1/CYP11B2 gene inherited as an autosomal dominant trait. The hybrid
gene results from an asymmetrical crossing over between the highly homologous CYP11B1 (encoding
11β-hydroxylase) and CYP11B2 (encoding aldosterone synthase) genes and comprises 5′ sequences of
CYP11B1 (including the promoter region) and 3′ sequences of CYP11B2 (including the coding region
of aldosterone synthase). Thus, in FH type I, aldosterone synthase is ectopically expressed in the ZF
under the control of adrenocorticotropic hormone (ACTH) rather than restricted to the ZG under the
control of angiotensin II [13,14].
3.2. Familial Hyperaldosteronism Type II
Familial hyperaldosteronism type II (FH type II) was first described by Stowasser et al. [15] in
a kindred with an autosomal dominant form of PA. Other kindreds were subsequently described
and a linkage with a locus on chromosome 7p22 was reported in some but not all families but
sequencing the entire linked locus did not identify the genetic cause [16]. In 2018, Scholl et al. [17]
identified the genetic variant responsible in the original kindred with FH type II described by
Michael Stowasser as a heterozygous variant of the CLCN2 gene that caused early-onset primary
aldosteronism and hypertension often with hypokalaemia. CLCN2 encodes CIC-2, a homodimer
voltage-gated chloride channel expressed in the adrenal gland predominantly in the ZG [17]. In the
original family with FH type II, eight individuals were carriers of the CLCN2 mutation (resulting
in the CIC-2 p.Arg172Gln substitution) and of these, seven tested positive with a screening test for
primary aldosteronism (elevated aldosterone-to-renin ratio). One carrier for the CIC-2 p.Arg172Gln
variant had a normal aldosterone-to-renin ratio, and therefore did not have primary aldosteronism,
indicating an incomplete penetrance of the allele. Scholl et al. found the p.Arg172Gln substitution
in an additional kindred and two further cases of p.Arg172Gln mutations (1 occurring de novo) in
2 unrelated patients with early-onset PA [17] as well as other CLCN2 variants encoding 4 different
mutations in CIC-2 (a de novo p.Met22Lys mutation, p.Tyr26Asn, p.Ser865Arg and p.Lys362del).
At the same time, Fernandes-Rosa et al., reported a de novo heterozygous p.Gly24Asp mutation in
the CIC-2 chloride channel associated with PA [18]. Electrophysiological recordings showed that the
mutated CIC-2 channels display modified gating resulting in increased chloride efflux compared with
wild-type CIC-2 channels. The increased chloride efflux leads to depolarization of adrenocortical cells,
activation of voltage-dependent Ca2+ channels, Ca2+ influx, increased CYP11B2 gene expression and
aldosterone production.
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3.3. Familial Hyperaldosteronism Type III
Choi et al. identified the genetic basis of familial hyperaldosteronism type III (FH type III) in
2011 by next-generation sequencing [6]. A gain-of-function mutation in the KCNJ5 gene (encoding the
G-protein-coupled inwardly rectifying potassium channel GIRK4) was identified in the male index case
and his two daughters. The mutation results in the substitution of a threonine residue (p.Thr158Ala)
located just above the selectivity filter of the channel pore which interferes with the Thr158-Pro128
hydrogen bonding [6]. Patch clamp recordings of human embryonic kidney cells expressing the
mutated GIRK4 p.Thr158Ala channel showed that the mutation results in a loss of selectivity for K+
and permissively allows the passage of Na+ resulting in membrane depolarization [6]. In adrenal
cells, membrane depolarization leads to the opening of voltage gated Ca2+ channels and Ca2+ influx
activating the Ca2+ signalling pathway and aldosterone production. Expression of GIRK4 p.Thr158Ala
in the human adrenocortical carcinoma cell line (HAC15) caused a marked increase in aldosterone
secretion that was dependent on membrane depolarization and Na+ and Ca2+ influx [19]. Until 2017,
22 patients with FH type III were described in the literature from 12 families [20]. Notable is that over
half of the patients described with FH type III (14 of 22 cases occurring in 7 of 12 families) carried
mutations of the Gly151 residue (p.Gly151Glu or p.Gly151Arg) in the GlyTyrGly motif implicated in
K+ selectivity [21].
3.4. Familial Hyperaldosteronism Type IV
Familial hyperaldosteronism type IV (FH type IV) is caused by gain-of-function mutations in
Cav3.2, a T type Ca2+ channel encoded by CACNA1H. FH type IV was first identified in 2015 by
exome sequencing of 40 unrelated subjects with early-onset hyperaldosteronism and hypertension
(<10 years of age) [22]. Scholl et al. identified five subjects with the same heterozygous mutation
in CACNA1H encoding the Ca2+ voltage gated channel (Cav3.2) resulting in a Cav3.2 p.Met1549Val
substitution [16]. Comparisons of whole cell patch clamp recordings of Cav3.2 p.Met1549Val and
wild-type Cav3.2 expressed in human embryonic kidney cells showed that the p.Met1549Val mutation
causes an impairment of channel activation and inactivation. The mutant channel displayed slightly
slower activation and much slower inactivation time constants compared with the wild-type channel
as well as a tail current indicating that a proportion of the mutated channels remain non-inactivated.
These properties would lead to an increase in Ca2+ influx in adrenal ZG cells and signal an increase
in aldosterone production. Validation of this concept was subsequently demonstrated by the same
group by expression of the Cav3.2 p.Met1549Val mutation in human adrenocortical (HAC15) cells
which resulted in an increase in CYP11B2 gene transcription and aldosterone secretion relative to cells
expressing the wild-type channel [23]. Following the discovery by Scholl, additional mutations in
CACNA1H were described involving a substitution of the same Met1549 residue (Met1549Ile) or other
amino acid residues (Ser196Leu, Val1951Glu and Pro2083Leu) [24].
4. Somatic Mutations in Aldosterone-Producing Adenomas
The most frequent genetic variation in APA is a somatic mutation of the KCNJ5 gene [25].
First identified by Choi et al. in 2011 by exome sequencing, mutations in KCNJ5 were identified
in 8 of 22 APA resulting in GIRK p.Gly151Arg or p.Leu168Arg mutations [6]. Both mutations were
demonstrated to interfere with the selectivity filter of the channel pore and result in membrane
depolarization causing the opening of voltage gated Ca2+ channels in adrenal glomerulosa cells and
Ca2+ influx [6]. Somatic KCNJ5 mutations are found at a prevalence of 40–50% [26–30] although
a higher prevalence has been reported in populations from Japan and China [31,32]. Following
the description of the KCNJ5 mutations, the application of next generation sequencing rapidly
identified additional somatic mutations associated with aldosterone overproduction in sporadic
PA. These include heterozygous gain-of-function mutations in Cav1.3 (the α1D subunit of the
L-type voltage-dependent calcium channel) encoded by CACNA1D [8,9] and the ion transporters,
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Na+/K+-ATPase (encoded by ATP1A1) and Ca2+-ATPase (encoded by ATP2B3) [7,8]. These mutations
result in an increase in intracellular Ca2+ concentration thereby causing an increase in transcription of
the CYP11B2 gene that encodes aldosterone synthase. Activating mutations in exon 3 of CTNNB1 that
encodes β-catenin have been identified in APAs as well as in other adrenal tumours [33]. Despite these
major advances, the mechanisms underlying the deregulated cell growth of APAs are probably not
explained by somatic mutations and the GIRK4 Thr158Ala mutation does not enhance proliferation of
adrenal cells in vitro [19]. Herein we discuss the transcriptome studies that have identified genes and
signalling pathways that may function in the pathophysiology and pathogenesis of APA.
5. Gene Expression Profiling
Gene expression studies have identified genes with a potential role in the pathogenesis and
pathophysiology of APAs (Table 2). Despite inter-study heterogeneity of gene expression data, which
may be accounted for by the use of different reference tissues (adjacent cortex or normal adrenal tissue
or, in some cases, non-functioning adrenocortical adenomas) and different diagnostic criteria [34–38],
such studies have proven valuable in the identification of genes and signalling pathways with a
potential role in the pathogenesis and pathophysiology of APAs.
Gene expression studies employing microarrays have shown a higher expression of CYP11B2
in APA compared with normal adrenals [39–41] and by SAGE (serial analysis of gene expression) in
an APA compared with adjacent cortical tissue [42]. However, another study of APA transcriptomes
reported two distinct and opposing expression profiles for genes encoding steroidogenic enzymes
with CYP11B2 displaying increased or decreased expression levels with respect to normal adrenal
tissue [43]. This apparent paradoxical decrease of the gene expressing aldosterone synthase in a
tumour that overexpresses aldosterone may be accounted for by sampling areas of the normal adrenal
reference tissue. In fact, these may contain aldosterone-producing cell clusters (APCC) that express
high levels of CYP11B2 with somatic CACNA1D, ATP1A1 or ATP2B3 mutations [44–46]. Conversely
large APA with low expression of CYP11B2 that give rise to inappropriate aldosterone production
might occur. Another possibility is that non-APA nodules were used in the study due to non-selective
diagnostic criteria.
Many studies have described an association of somatic APA mutations with histological
phenotype. APAs carrying KCNJ5 mutations have been widely reported to comprise predominantly
large lipid-rich ZF-like cells (Figure 2) [8,47–50]. Some studies have also described a predominance of
small compact ZG-like cells in APA harbouring CACNA1D, ATP1A1 or ATP2B3 mutations [8,27,49,51]
and somatic APA genotype is associated with plasma steroid profiles [52]. Such genotype-phenotype
associations indicate that APA genotype may influence transcriptome signatures. Histological
differences between large lipid-rich ZF-like cells and small compact ZG-like cells in APA are shown in
Figure 2.
Figure 2. Histopathological phenotype of aldosterone-producing adenomas. Haematoxylin and eosin
staining of an aldosterone-producing adenoma showing large lipid-rich cells of the ZF type (indicated
with arrows) (panel A) or a predominance of smaller compact cells of the ZG type (indicated with
arrows) (panel B).
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No differences in the transcriptome profiles of APA with and without KCNJ5 mutations were
initially described [26]. However, later studies reported distinct expression profiles of APA with KCNJ5
mutations compared with APA without KCNJ5 mutations (with higher CYP11B2 expression in the
tumours with KCNJ5 mutations) [53]. Different expression profiles were reported in APA with ATP1A1
and ATP2B3 mutations relative to APA with KCNJ5 mutations (with higher CYP11B2 expression
in the tumors with ATP1A1 and ATP2B3 mutations) [54]. Azizan et al. [35] demonstrated marked
differences in CYP17A1 gene expression from microarrays, validated by real-time PCR, in APA with
a ZF phenotype compared to those APA with a ZG phenotype [47]. If CYP17A1 and CYP11B2 are
expressed in the same cell then cortisol can be metabolized further to produce the hybrid steroids
18-hydroxycortisol and 18-oxocortisol [55]. Higher levels of these hybrid steroids are associated with
FH type I and FH type III (although not in all cases) and in patients with an APA with a KCNJ5
mutation [12,52].
CYP17 expression in APA has been shown to be associated with APA phenotype with marked
upregulation in adenomas comprising predominantly ZF-type cells [47]. NURR1 (NR4A2, encoding
Nur-related factor 1) and NGFIB (NR4A1, encoding nerve growth factor IB), genes that encode
transcription factors playing a key role in the regulation of CYP11B2 gene transcription [56],
are upregulated in APA. Also, genes encoding the nuclear receptor transcription factors SF-1 (NR5A1)
and DAX1 (NR0B1) that are essential for adrenal development and steroidogenesis, are upregulated in
APA [39]. Although low DAX1 expression in adrenocortical tumours is associated with aldosterone
production [57]. A target gene of SF-1, VSNL1 [58], is upregulated in APA and VSNL1 in vitro
overexpression in the NCI H295R cell line results in an increase in aldosterone production under both
basal and angiotensin II-stimulated conditions [59].
Several genes encoding G-protein-coupled receptors are among the genes upregulated in APA,
including those encoding the luteinizing hormone receptor (LH-R encoded by LHCGR), gonadotropin
releasing hormone receptor (GnRHR encoded by GNRHR), serotonin receptor 4 (HTR4), melanocortin
2 receptor (MC2R), and the angiotensin II type 1 receptor (AGTR1) [60]. Overexpression of LH-R
in the adrenocortical carcinoma NCI H295R cell line causes a concentration-dependent increase in
CYP11B2 expression after stimulation with luteinizing hormone [40]. Accordingly, the expression of
LH-R and GnRHR in APAs has been proposed to be related to increased aldosterone production during
pregnancy [61]. Therefore, the presence of activating APA CTNNB1 mutations might contribute to an
abnormal receptor activation [60].
NEFM, encoding the medium neurofilament protein, is highly upregulated only in APAs without
KCNJ5 mutations and is selectively expressed in the ZG and in APA comprised of predominantly ZG
cells [62,63]. Dopamine regulates aldosterone production via activation of its G-protein-coupled
receptor (GPCR) subtypes and silencing of NEFM amplified aldosterone stimulation by a DR1
(dopamine receptor subunit 1) agonist and aldosterone secretion in response to the DR1 agonist
was greater in primary cultures of APAs composed of primarily ZF cells compared with cultures
of APAs with ZG cells. These data indicate a role for NEFM in aldosterone production and cell
proliferation [63].
Analysis of the methylome of APAs demonstrated hypomethylation of GPCR genes and a strong
association of promoter hypomethylation of the HTR4 and PTGER1 genes with the upregulation of
mRNA levels, validated by real-time PCR, was demonstrated in APAs compared with non-functioning
adrenocortical adenomas [64]. Methylation of HTR4 and PTGER1 was significantly inversely correlated
with their respective mRNA expression levels [64]. The most hypomethylated promoter in APA is
the PCP4 (encoding purkinje cell protein 4) promoter with demethylation associated with enhanced
gene transcription [65]. CYP11B2 was also extensively hypomethylated in APAs [64] but although
hypomethylation was not associated with gene expression levels in this study it could facilitate gene
transcription [64]. In contrast, Howard et al., reported hypomethylation of APAs with hypomethylation
and overexpression of CYP11B2 [64].
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Calcium is a key intracellular messenger for aldosterone production and the intracellular Ca2+
signaling pathway is independent of the renin–angiotensin–aldosterone system in APAs [66]. A number
of genes involved in Ca2+ signaling or Ca2+ sequestration have been reported as upregulated in
APAs and are described in more detail below. VSNL1 that encodes a Ca2+-sensor protein and a
target of the nuclear receptor SF-1 [58] was one of several upregulated genes in APAs by microarray
analysis compared with normal adrenals validated by real-time PCR [41]. In NCI H295R adrenal
cells, overexpression of VSNL1 resulted in an upregulation of CYP11B2 gene expression under both
basal and angiotensin II-stimulated conditions thereby implicating a role for VSNL1 in aldosterone
production. Analysis of a larger sample set of tumours showed that VSNL1 was overexpressed in
APAs carrying a KCNJ5 mutation compared with those APA without a KCNJ5 mutation. A potential
role for the calcium sensor in the protection of cells in an adenoma via Ca2+-related anti-apoptotic cell
death mechanisms was hypothesized [59]. The expression of the VSNL1 protein in an APA (carrying a
KCNJ5 mutation) that displays strong CYP11B2 immunostaining is shown in Figure 3.
Figure 3. VSNL1 and CYP11B2 immunohistochemistry. An aldosterone-producing adenoma with
a KCNJ5 mutation stained with haematoxylin and eosin panels (A,B); immunostained for VSNL1,
panels (C,D); and for CYP11B2 panels (E,F). The VSNL1 antibody was from Merck and the CYP11B2
was a kind gift from Prof Celso Gomez-Sanchez, University of Mississippi, Oxford, MS, USA.
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The CALN1 gene, that encodes the Ca2+ binding protein calneuron 1, has been reported as
upregulated in APA in two transcriptome studies [41,67]. CALN1 was shown to potentiate aldosterone
production and silencing CALN1 led to a decrease in Ca2+ storage in the endoplasmic reticulum and
abrogated angiotensin II-mediated aldosterone secretion in an adrenocortical carcinoma cell line [41].
CALM2 encoding calmodulin 2 is a Ca2+-binding protein expressed in a wide-range of tissues
involved in signalling, cell cycle progression and proliferation. CALM2 was highly upregulated in
a transcriptome comparison of APAs with the adjacent ZG [42]. The increased expression of PCP4
in APA cells is likely to play a role in APA pathophysiology because PCP4 modulates Ca2+-binding
by calmodulin and activates the calcium-calmodulin cascade leading to an increased expression of
CYP11B2 [68].
GSTA1 (encoding glutathione-S-transferase, an enzyme that protects cells from reactive oxygen
species, ROS) gene expression is inversely correlated with the level of aldosterone production in APAs
with a KCNJ5 mutation and appears to regulate aldosterone secretion via ROS and Ca2+ signalling [69].
GSTA1 overexpression suppressed aldosterone biosynthesis, while silencing of GSTA1 increased
aldosterone production through increasing ROS, superoxide, H2O2 levels, Ca2+ influx and the
expression of CAMK1 (encoding Ca2+/calmodulin dependent protein kinase 1) and the transcription
factors NR4A1 (also called NGFIB) and NR4A2 that regulate CYP11B2 gene expression [69].
The epidermal growth factor-like teratocarcinoma-derived growth factor-1 gene (TDGF1) was
identified as the most highly expressed gene in APAs compared with normal adrenals by microarray
analysis [41]. TDGF1 was also identified as upregulated in an APA relative to the paired adjacent
cortex by serial analysis of gene expression [41]. Overexpression of TDGF1 in NCI H295R adrenal cells
activated the PI3K-Akt signalling pathway and led to an increase in aldosterone production, indicating
a potential role in APA pathophysiology [41]. The activation of PI3K/Akt mTOR signalling, a pathway
with a known role in cell proliferation, was also reported in patients with PA [41].
Wnt plays a key role in the development of the adrenal cortex and the dysregulation of this
signalling pathway is associated with tumorigenesis [70]. The Wnt/β-catenin pathway is constitutively
activated in around 70% of APAs [71] with the decreased expression on the Wnt inhibitor SFRP2
(encoding secreted frizzled related protein 2) likely playing a role in the deregulated Wnt/β-catenin
signalling [72]. SFRP2 was also four-fold down-regulated in APAs compared with normal adrenals
in an oligonucleotide microarray [72]. Mice with an ablation of Sfrp2 display enhanced aldosterone
production [72]. β-catenin appears to mediate aldosterone production by increasing the transcription of
several genes including AT1R, CYP21 and CYP11B2 as well as upregulating expression of transcription
factors NURR1 (NR4A2) and NUR77 (NR4A1) [72].
NPNT (nephronectin), a secreted matrix protein, was most highly expressed in APAs with a ZG
phenotype with CTNNB1 mutations. Thereby it may represent a potential biomarker to recognize a
subtype of APAs and indicates a further mechanism by which the Wnt/β-catenin signalling pathway
may upregulate aldosterone production [72]. These studies show that aberrant Wnt/β-catenin pathway
activation is associated with APA development and suggests that the Wnt/β-catenin signalling
mediates aldosterone production at multiple levels [71].
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Table 2. Differentially expressed genes in aldosterone-producing adenomas and their reference tissues
used in transcriptome studies.
Gene Encoded Protein and Description Reference Tissue Ref.
Upregulated Genes
CYP11B2 Aldosterone synthase- steroid hydroxylase cytochrome P450 enzymewith 11β-hydroxylase, 18-hydroxylase and 18-oxidase activities AAC; NLA [34,39–41]
Calcium Signaling
VSNL1 Visinin-like 1, calcium sensor protein of visinin/recoverin subfamily NLA [59]
CALN1 Calneuron 1, calcium-binding protein with high similarity tocalmodulin family NLA [41,67]
CALM2 Calmodulin 2, calcium-binding protein of calmodulin family. Adjacent ZG [42]
PCP4 Purkinje cell protein 4, regulates calmodulin activity by modulatingcalcium binding by calmodulin NFA [68]
Nuclear receptor Transcription Factors
NR4A1 Nuclear receptor subfamily 4 group A member 1; steroid-thyroidhormone-retinoid receptor superfamily. WT-KCNJ5-APAs [56]
NR4A2 Nuclear receptor subfamily 4 group A member 2; steroid-thyroidhormone-retinoid receptor superfamily. WT-KCNJ5-APAs [56]
NR5A1 Nuclear receptor subfamily 5 group A member 1 (SF1); transcriptionalactivator of sex determination. AAC [39]
NR0B1 Nuclear receptor subfamily 0 group B member 1 (DAX1); functions inproper formation of adult adrenal gland formation. AAC [39]
G-protein-coupled Receptors
LHCGR Luteinizing hormone/choriogonadotropin receptor NLA [60]
GNRHR Gonadotropin releasing hormone receptor NLA [60]
HTR4 5-hydroxytryptamine receptor 4 NLA; NFA [60,64]
PTGER1 Prostaglandin E receptor 1 NFA [64]
MC2R Melanocortin 2 receptor NLA [60]
AGTR1 Angiotensin II receptor type I NLA [60]
Others
NEFM Medium neurofilament protein- biomarker of neuronal damage KCNJ5-mut APAs; ZF-likeAPAs [62,63]
TDGF1 Teratocarcinoma-derived growth factor 1- signaling protein thatfunctions in development and tumor growth NLA [41]
NPNT Nephronectin, a secreted matrix protein NLA [72]
Downregulated Genes
GSTA1 Glutathione S-transferase alpha 1- member of a family of enzymes thatprotect cells from reactive oxygen species WT-KCNJ5-APAs; NLA [69]
SFPR2 Secreted frizzled related protein 2- agonist of Wnt signaling NLA [72]
AAC: adjacent adrenal cortex; APAs: aldosterone-producing adenomas; KCNJ5-mut APAs: APAs with KCNJ5
mutations; NFA: non-functioning adrenocortical adenomas; NLA: normal adrenals; WT-KCNJ5 APAs: APAs with
wild type KCNJ5 gene; ZF: zona fasciculata; ZG: zona glomerulosa.
6. Single Nucleotide Polymorphisms
Single nucleotide polymorphisms (SNPs) are the most frequent genetic variation in the human
genome. A rare nonsynonymous SNP (rs7102584) resulting in a GIRK4.p.Glu282Gln substitution
was identified in 12 of 251 patients (5%) with sporadic PA (9 with bilateral and 3 with unilateral PA)
compared with a prevalence of 2% in the 1000 genomes cohort [73]. Five common SNPs of the KCNJ5
gene (rs6590357, rs4937391, rs3740835, rs2604204, and rs11221497) were found in patients with sporadic
PA and essential hypertension and a significant association of the rs2604204 variant with sporadic PA
in Chinese males was found indicating a potential role for this polymorphism in the pathogenesis of
sporadic PA in this specific subgroup of patients [74].
7. Influence of Genetics and Genomics on Surgical Outcome
High blood pressure may persist after adrenalectomy due to contributory factors other than PA
and the surgical cure rate of patients with APAs varies widely. Comparison of the transcriptomes
of APAs with normal adrenals identified two subgroups of APAs based on their expression profiles
(low versus high mRNA levels) of genes encoding steroidogenic enzymes. APAs with a low level of
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CYP11B2 gene transcription are associated with a longer known duration of hypertension and a lower
rate of long-term cure [43].
Microarray analysis identified differentially expressed genes in a comparison of the transcriptomes
of APAs from patients with persistent hypertension after adrenalectomy with that of patients with
APA who were cured by surgery [75]. The differentially expressed genes were associated with five
different pathways that included lipid metabolism and cell differentiation and indicate the possibility
of using genomic approaches to identify drug targets and prognostic markers [75].
A number of studies have investigated the effect of KCNJ5 mutational status as a marker for
surgical outcome. In a prospective study by the TAIPAI (Taiwan Primary Aldosteronsim Investigation
study group) of 108 patients that were divided into KCNJ5 mutated and non-mutated groups, patients
with an APA carrying a KCNJ5 mutation aged between 37 and 60 years may have an advantage in
blood pressure response to surgery but mutation status is not associated with an improvement in
arterial stiffness [76].
Cardiovascular complications before and after unilateral adrenalectomy in patients harboring
APAs with and without KCNJ5 gene mutations were evaluated in a Japanese population.
The KCNJ5-mutated group displayed a significant improvement in left ventricular mass index which
was independently associated with the presence of APA KCNJ5 mutations whereas the group without
KCNJ5 mutations had no such improvement [77]. A higher left ventricular mass index and plasma
aldosterone concentration in patients with APA KCNJ5 mutations relative to those without KCNJ5
mutations has also been reported [35]. Despite the increased cardiac damage, patients with KCNJ5
mutations exhibited a decrease of blood pressure and plasma aldosterone concentrations and a
regression of left ventricular mass index similar to the KCNJ5 wild type group after adrenalectomy [35].
Another study reported an association of APA KCNJ5 mutations with lower blood pressure and
the higher likelihood of cure of PA by adrenalectomy relative to patients with APA without KCNJ5
mutations [36].
8. Conclusions and Perspectives
Major discoveries have been made in the field of PA research over the last few years mainly due
to the application of next-generation sequencing methods. Four familial forms of hyperaldosteronism
are now recognized with the genetic basis of three of these uncovered by exome sequencing.
Somatic mutations have been identified in ion channels and transporters that alter intracellular ion
homeostasis and drive the constitutive aldosterone production in over half of aldosterone-producing
adenomas. Differential gene expression studies have further highlighted key signalling pathways
and molecular mechanisms that may drive cell proliferation and aldosterone overproduction in
aldosterone-producing adenomas. Transcriptome analysis methods may have a future application in
the identification of prognostic markers to identify post-operative cardiovascular events.
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